Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue and Photodynamic Therapy in SARS-CoV-2
NCT04933864Phase 1Completed
- Sponsor
- Sechenov First Moscow State Medical University
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of methylene blue in coronavirus disease 2019 (COVID-19), sponsored by Sechenov First Moscow State Medical University. Primary endpoint: Percentage of participants with negative quantitative Polymerase Chain Reaction test on SARS-CoV-2 at 2 days. Started Apr 2020; status: completed.
02
Drugs
methylene blue
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04933864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933864.